Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (481-490 of 622) with videos related to

Pageof 63
Sort By:
Acta Oncologica (Stockholm, Sweden)|February 15, 2021
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection marginsRebecca K Bott, Kerri Beckmann, Janine Zylstra, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.
The British Journal of Surgery|May 13, 2022
Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinomaArnaldo N S Silva, Yuichi Saito, Takaki Yoshikawa, et al.
The Journal of Molecular Diagnostics : JMD|March 10, 2015
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissuesShenli Zhang, Iain B Tan, Nur S Sapari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Pageof 63

Showing results (481-490 of 622) with videos related to

Sort By:
Pageof 63
Acta Oncologica (Stockholm, Sweden)|February 15, 2021
Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection marginsRebecca K Bott, Kerri Beckmann, Janine Zylstra, et al.
British Journal of Haematology|May 22, 2020
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trialMary Gleeson, Nicholas Counsell, David Cunningham, et al.
British Journal of Cancer|April 21, 2026
Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trialAnderley Gordon, Amina Tran, Caroline Fong, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.
The British Journal of Surgery|May 13, 2022
Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinomaArnaldo N S Silva, Yuichi Saito, Takaki Yoshikawa, et al.
The Journal of Molecular Diagnostics : JMD|March 10, 2015
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissuesShenli Zhang, Iain B Tan, Nur S Sapari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.
The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.
Pageof 63